Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio

By /

Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.

Scroll to Top